PRESS RELEASES

4D Molecular Therapeutics Announces Presentation of Preclinical Data at the 6th International Update on Fabry Disease and Provides Clinical Update

- Novel vector, 4D-C102, demonstrates superior performance compared to commonly used AAV1, AAV8, and AAV9 - - Fabry product candidate, 4D-310, is on track for anticipated clinical trial initiation in 2020 - Superior transduction of 4DMT’s novel vector, 4D-C102, ...

4D Molecular Therapeutics Expands Leadership Team with Appointments and Promotions of Key Executives

Company adds manufacturing and quality expertise and broad financial, operational and legal experience with the appointments of Fred Kamal, PhD as chief technical officer and head of regulatory and quality and of August Moretti as chief financial officerCompany announces ...

4D Molecular Therapeutics Announces Collaboration to Advance Gene Therapies for Retinal Diseases with Oregon Health & Science University’s Casey Eye Institute and Oregon National Primate Research Center

Emeryville, CA – December 6, 2018 - 4D Molecular Therapeutics (4DMT), a world-leader in Therapeutic Vector Evolution for adeno-associated virus (AAV) gene therapy vector discovery and product development today announced a research and development collaboration with the Casey Eye Institute ...

4D Molecular Therapeutics Announces FDA Orphan Drug Designation Granted to 4D-110 for the Treatment of Choroideremia

Emeryville, CA – November 16, 2018 - 4D Molecular Therapeutics (4DMT), a world-leader in Therapeutic Vector Evolution for adeno-associated virus (AAV) gene therapy vector discovery and product development today announced that the U.S. Food and Drug Administration (FDA) has ...

4D Molecular Therapeutics to Participate at Upcoming Investor Conferences

Emeryville, CA – November 6, 2018 - 4D Molecular Therapeutics (4DMT), a world-leader in Therapeutic Vector Evolution for adeno-associated virus (AAV) gene therapy vector discovery and product development today announced that company management will participate at the following upcoming investor ...